How to Get Alprostadil (Caverject/MUSE) in New Hampshire

What Alprostadil Does and Why NH Prescribers Use It

Alprostadil is synthetic prostaglandin E1. It relaxes smooth muscle in the corpus cavernosum, dilates cavernosal arteries, and produces an erection within 5 to 20 minutes that is independent of libido or nervous-system signaling. That mechanism makes it suitable for men whose erectile dysfunction (ED) has a vascular, neurogenic, or post-prostatectomy origin and who have not responded to oral sildenafil or tadalafil.

The landmark randomized controlled trial by Linet and Ogrinc (NEJM, 1996, N=296) found that 94% of injections with alprostadil produced erections sufficient for intercourse, compared with 11% on placebo injections (P<0.001) [1]. That single-trial response rate anchored alprostadil as a first-line injectable therapy in American Urological Association ED guidelines and drove FDA approval of Caverject in 1995 and MUSE in 1997 [2].

New Hampshire urologists and primary care physicians routinely prescribe alprostadil when a patient has tried two or more oral PDE5 inhibitors at maximum dose and failed, when nitrate co-administration makes PDE5 inhibitors unsafe, or when post-surgical neuropathy has interrupted the nitric-oxide pathway entirely. The drug does not require an intact nerve reflex arc to work. That is a practical advantage no oral agent can match.

Clinical data show a 70% to 80% long-term satisfaction rate among couples who continue alprostadil therapy beyond six months [3]. Priapism (erection lasting more than 4 hours) occurs in roughly 1% of self-injected doses when the dose has been titrated correctly in an office setting [1].

New Hampshire Prescribing Rules: Who Can Write the Script

Any MD, DO, NP (nurse practitioner), or PA (physician assistant) licensed by the New Hampshire Board of Medicine or Board of Nursing may prescribe alprostadil, provided they have an established patient relationship, which telehealth visits now satisfy under NH RSA 329:1-d and the NH Board of Medicine's 2020 telehealth guidance [4].

New Hampshire does not restrict prescribing of alprostadil to urologists only. Primary care physicians write a significant share of these prescriptions statewide. However, for the intracavernosal form (Caverject, Edex), the FDA-approved prescribing information specifies that the first injection must be administered in a medical office so the dose can be titrated and the patient observed for hypotension or prolonged erection [2]. Telehealth providers comply with this requirement by directing NH patients to a local urology office, urgent care, or compounding pharmacy that offers clinical services for the titration visit. MUSE (intraurethral suppository) carries a lower procedural burden and some telehealth practices permit it to be initiated at home after a video consultation.

The AUA 2018 ED guideline states: "Vacuum erection devices and intracavernosal injections should be offered to patients who do not respond to or cannot use PDE5 inhibitors" [5]. That guideline language gives NH prescribers clear clinical standing to move directly to alprostadil without exhausting every oral option, provided the clinical picture warrants it.

NPs and PAs in New Hampshire have full prescriptive authority for non-controlled substances. Alprostadil is not a controlled substance under federal or NH law, so NPs and PAs may prescribe it without physician co-signature [4].

Step-by-Step: Getting an Alprostadil Prescription in New Hampshire

Getting a prescription follows a predictable four-step sequence regardless of whether you use a telehealth provider or a local NH urology practice.

Step 1: Book an intake visit. Schedule a same-day or next-day telehealth visit with a platform licensed in NH, or call a urology office in Manchester, Concord, Nashua, or Portsmouth. Video visits take 15 to 25 minutes on average.

Step 2: Complete the intake questionnaire. Most providers use the International Index of Erectile Function-5 (IIEF-5) validated screening tool. Scores of 21 or below indicate ED [6]. You will also be asked about cardiovascular history, current medications (especially nitrates, anticoagulants, and antihypertensives), and prior PDE5 inhibitor use. Accurate answers shorten the prescribing timeline.

Step 3: Provide labs or complete point-of-care testing. See the dedicated lab section below. Many telehealth platforms accept recent results from your primary care provider.

Step 4: Receive the prescription and fill it. The prescriber sends the script electronically to your preferred NH pharmacy or to a licensed mail-order/compounding pharmacy. Caverject and MUSE brand products are available at most major NH retail chains. Compounded alprostadil vials (typically 10 mcg/mL to 40 mcg/mL) are available from 503A pharmacies with an NH-licensed prescriber's order.

Labs and Clinical Workup Required Before Prescribing

Most NH providers require a targeted lab panel before initiating alprostadil. The goal is to rule out reversible causes of ED and to establish cardiovascular baseline safety.

Standard pre-prescribing labs include: fasting glucose or HbA1c (diabetes is present in up to 35% of men with ED) [7], total and free testosterone (hypogonadism contributes to ED in roughly 20% of cases) [8], a lipid panel, and a basic metabolic panel if renal disease is suspected. Some practices add TSH and prolactin if the history suggests a pituitary origin.

A cardiovascular history and resting blood pressure measurement are mandatory. The Princeton Consensus Panel III guideline classifies men into low, intermediate, and high cardiovascular risk before prescribing any ED therapy [9]. Men in the intermediate or high-risk category should be referred to cardiology before alprostadil is started, because the hemodynamic response to an erection is roughly equivalent to climbing two flights of stairs, placing moderate demand on the heart.

You do not need a penile duplex Doppler ultrasound to receive an alprostadil prescription in New Hampshire. That test is reserved for surgical planning or when vasculogenic ED needs to be confirmed before prosthesis candidacy is assessed.

The American Diabetes Association recommends annual testosterone screening in men with type 2 diabetes and ED [7]. If your HbA1c comes back above 6.5%, your prescriber may want to optimize glycemic control alongside alprostadil therapy.

Telehealth Providers Prescribing Alprostadil in New Hampshire

New Hampshire explicitly permits telehealth prescribing for non-controlled substances after a valid patient-provider relationship is established via synchronous audio-video visit. No prior in-person visit is required to establish that relationship under current NH law [4].

Several national men's health telehealth platforms are licensed to prescribe in New Hampshire and can initiate MUSE without requiring an in-person titration. For Caverject, these platforms typically coordinate with a local NH provider for the mandatory first-injection office visit, after which the patient self-injects at home.

Typical telehealth workflow for an NH resident:

1. Complete online intake form and IIEF-5 questionnaire.
2. Upload or order labs (some platforms use Labcorp or Quest draw sites; there are Quest locations in Manchester, Nashua, and Concord).
3. Attend 15 to 25 minute video visit with an NH-licensed prescriber.
4. Prescription sent to your pharmacy or mailed from a partner compounding pharmacy.
5. For Caverject: schedule one in-person injection training session locally.

Turnaround from first visit to medication in hand runs 3 to 7 business days for most NH patients using this workflow, based on standard pharmacy processing and shipping timelines.

503A Compounding Pharmacies and Alprostadil in New Hampshire

Brand-name Caverject and Edex can be expensive, ranging from $350 to $600 per month for typical use. Compounded alprostadil from a 503A pharmacy often reduces that cost to $80 to $150 per month for an equivalent supply.

Under USP 795 and 797 standards enforced by the New Hampshire Board of Pharmacy, licensed 503A pharmacies may compound alprostadil in sterile injectable form for individual patient prescriptions [10]. The key requirement is that a valid, patient-specific prescription from an NH-licensed prescriber must accompany the order. 503A pharmacies cannot compound in bulk or sell without a prescription.

Several NH-licensed 503A pharmacies compound alprostadil intracavernosal solution at concentrations ranging from 10 mcg/mL to 40 mcg/mL. Some also prepare tri-mix (alprostadil plus papaverine plus phentolamine), which is outside the branded product line but commonly prescribed by NH urologists when alprostadil monotherapy produces a suboptimal response.

NH pharmacies that hold an out-of-state 503A license may also ship compounded alprostadil to NH residents, provided they are registered with the NH Board of Pharmacy under RSA 318:18 and comply with cold-chain shipping requirements. Alprostadil requires refrigeration (2 to 8 degrees Celsius) during transit [2].

The FDA's guidance on 503A compounding distinguishes patient-specific compounding from mass production. Alprostadil is not on FDA's list of drugs that cannot be compounded (the "demonstrably difficult to compound" list), so compounding remains permissible [11].

Dosing: Caverject vs. MUSE

Understanding the dosing difference between the two formulations helps patients and prescribers choose the right option.

Caverject (intracavernosal injection): Starting dose is typically 1.25 mcg to 2.5 mcg for neurogenic ED or 5 mcg for vasculogenic ED, titrated upward in a clinical setting to achieve an erection lasting 60 minutes or less. The FDA-approved maximum single dose is 60 mcg, though most men respond in the 10 mcg to 20 mcg range [2]. Injection frequency is limited to once per 24 hours and no more than three times per week to minimize fibrosis risk.

MUSE (intraurethral suppository): Available in 125 mcg, 250 mcg, 500 mcg, and 1000 mcg pellets. Median effective dose in clinical trials was 500 mcg [12]. Response rates are lower than intracavernosal injection (30% to 65% vs. 70% to 90%), but many patients prefer the non-injection route [12]. MUSE should not be used more than twice in 24 hours.

Onset is 5 to 10 minutes for Caverject and 10 to 20 minutes for MUSE. Duration is 30 to 60 minutes for most men at therapeutic doses.

Side effects differ by route. Caverject causes penile pain in roughly 30% of users (usually mild and transient) and carries a 1% priapism risk [1]. MUSE causes urethral burning in up to 36% of users and a lower priapism rate [12]. Systemic hypotension is more common with MUSE because some alprostadil is absorbed into the systemic circulation via the urethral mucosa [2].

The AUA recommends that patients using MUSE be observed in-office for hypotension after the first administration [5]. NH telehealth providers handling MUSE initiation often ask patients to use a blood pressure cuff at home during the first dose and to call if they feel lightheaded.

Insurance, Prior Authorization, and NH Medicaid

New Hampshire Medicaid does not cover alprostadil for erectile dysfunction. Private insurance coverage varies widely by plan. Many commercial plans classify alprostadil as a specialty drug and require prior authorization (PA) before dispensing.

A typical PA request for alprostadil in New Hampshire requires:

• Diagnosis code N52.9 (erectile dysfunction, unspecified) or a more specific ICD-10 code
• Documentation that at least one oral PDE5 inhibitor (sildenafil, tadalafil, vardenafil, or avanafil) was tried at maximum tolerated dose and failed or was contraindicated
• Lab results showing testosterone levels to rule out hypogonadism as sole cause
• The prescriber's attestation that alprostadil is medically necessary

Some NH plans also require documentation of cardiovascular clearance if the patient has known coronary artery disease. PA approval typically takes 3 to 10 business days. If denied, a peer-to-peer appeal between the prescriber and the insurance medical director succeeds in roughly 40% of cases based on published insurer data [13].

The manufacturer patient assistance program (Pfizer Rx Pathways) may reduce or eliminate cost for patients meeting income criteria. The application is available directly through Pfizer and does not require an NH-specific process.

What to Do If Your Prescription Is Denied or Delayed

Prescription denials for alprostadil in New Hampshire are almost always prior-authorization failures, not prescribing-authority issues. Three actions tend to resolve most denials within a week.

First, ask your prescriber to submit a peer-to-peer review call with the insurer's medical director. Success rates for ED medication PA appeals are higher when the prescriber can cite the documented PDE5 inhibitor failure and the Linet trial data showing 94% efficacy [1].

Second, ask for a bridge supply through a 503A compounding pharmacy while the appeal is pending. Compounded alprostadil does not go through the same insurance channel and can be dispensed immediately with a valid NH prescription.

Third, check GoodRx or Cost Plus Drugs pricing for generic alprostadil injection. Generic injectable alprostadil (10 mcg/mL, 1 mL vials) has been available at several NH retail pharmacies at $80 to $130 per two-vial pack, far below the brand price.

Monitoring During Alprostadil Therapy

Alprostadil therapy is not a one-time prescription and forget situation. The AUA 2018 guideline and the FDA label both recommend periodic follow-up to assess for fibrosis (Peyronie's-like plaques at the injection site), which occurs in roughly 2% to 3% of long-term users [5][2].

Follow-up visits should occur at 3 months after initiation, then every 6 to 12 months. At each visit the provider should examine the penis for nodules or curvature, review injection technique, and reassess the underlying cardiovascular and metabolic risk factors that drive ED progression.

Testosterone should be re-checked annually. If total testosterone falls below 300 ng/dL at any follow-up visit, concurrent testosterone replacement therapy may improve both sexual function and alprostadil response [8]. A 2016 meta-analysis in the Journal of Sexual Medicine (pooling data from 14 RCTs, N=2,298) found that testosterone normalization improved ED scores by a mean of 3.1 IIEF-5 points above PDE5 inhibitor or injection therapy alone [8].

Blood pressure should be measured at every follow-up visit, particularly for patients on antihypertensive regimens where alprostadil's vasodilatory effect may be additive.